medigraphic.com

2011, Number 4

<< Back Next >>

Rev Med Inst Mex Seguro Soc 2011; 49 (4)

Enfermedad tromboembólica venosa

Valdivia-Gómez GG

Language: Spanish
References: 34
Page: 383-392
PDF size: 60.62 Kb.


ABSTRACT

Venous thromboembolic disease (VTD) is a frequent medical problem. The VTD includes deep vein thrombosis (DVT), the posthrombotic syndrome (PTS) and pulmonary embolism (PE). The generation of a thrombus in the venous system, is caused by several abnormalities that induce the loss of the most important characteristic of the blood, the liquid state. DVT is due to the formation of a thrombus. Main causes for thrombus formation are thrombophilias which may be classified as primary and secondary. All thrombophilias may affect the homeostasis favoring a hypercoagulable state. In the XIX Century, Virchow classified all the causes of hypercoagulable states as follows: due to stasis of the venous blood flow, due to damage of the endothelium an a hypercoagulable clinical condition. Several risk factors for VTD has been described, during the hospitalization to both, medical and surgical conditions. Among the last, orthopedic and vascular surgery of the legs. Although nearly 50 % of DVTs are asymptomatic and 3 % of the patients with VTD develop PE and 30 % of them die. Thromboprophylaxis is the main strategy to prevent and to diminish the incidence of DVT and its complications. Thromboprophylaxis is useful to improve the quality of life of the patients at risk and it is an effective economical strategy for health care institutions.


REFERENCES

  1. Joffe HV, Goldhaber SZ. Upper-extremity deep vein thrombosis. Circulation 2002;106(14):1874-80.

  2. Virchow RLK. Thrombose und Embolie, Gefässentzündung und Septische Infection. Gesammelte Abhandlungen zur Wissenschaftlichen Medicin. Frankfurt am Main: Von Meidinger & Sohn; 1856. 219-732. Traducción en: Matzdorff AC, Bell WR. Thrombosis and embolie (1846-1856). Canton, Massachusetts: Science History Publications; 1998.

  3. Bundens WP. Bergan JJ, Halasz NA, Murray J, Drehobl M. The superficial femoral vein. A potentially lethal misnomer. JAMA 1995;274(16):1296-1298.

  4. Oger E. Incidence of venous thromboembolism in a community- based study in Western France. Thromb Haemost 2000; 83(5):657-660.

  5. Nicolaides AN, Arcelus J, Belcaro G, Bergqvist D, Borris LC, Buller HR, et al. Prevention of venous thromboemolism. European Consensus Statement, 1-5 November 1991, development at Oaley court Hotel Windsor, UK. Int Angiol 1992;11(3):151-159.

  6. Douketis J, Tosetto A, Marcucci M, Baglin T, Cosmi B, Cushman M, et al. Risk of recurrence after venous thromboembolism in men and women: patient level metaanalysis. BMJ 2011;342:d813

  7. Palareti G, Cosmi B, Lessiani G, Rodrigo G, Guazzaloca G, Brusi C, et al. Evolution of untreated calf deepvein thrombosis in high risk symptomatic outpatients: the blind, prospective CALTHRO Study. Thromb Haemost 2010;104 (5):1063-107.

  8. Kearon C. Natural history of venous thromboembolism. Circulation 2003;107(23 Suppl 1):122-130.

  9. Wells PS, Anderson DR, Bormanis J, Guy F, Mitchell M, Gray L, et al. Value of assessment of pretest probability of deepvein thrombosis in clinical management. Lancet 1997; 350(9093):1795-1798.

  10. Wells PS, Owen C, Doucette S. Does this patient have deep vein thrombosis? JAMA 2006;295(2):199-207.

  11. Offord R, Perry D. Handbook of anticoagulation. Australian: Science Press; 2002. p. 46.

  12. Büller HR, Davidson BL, Decousus H, Gallus A, Gent M, Piovella F, et al. Subcutaneous fondaparinux versus intravenous unfractionated heparion in the treatment of pulmonary embolism. N Engl J Med 2003;349(18):1695-1702.

  13. Büller HR, Davidson BL, Decousus H. Fondaparinux or enoxaparin for the treatment for initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med 2004;140(11):867-873.

  14. Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ, et al. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. (8th Edition) Chest 2008;133(6 Suppl):454s-545s.

  15. Panova-Noeva M, Falanga A. Treatment of thromboembolism in cancer patients. Expert Opin Pharmacother 2010;11(12): 2049-2058.

  16. Kearon C, Ginsberg JS, Julian JA, Douketis J, Solymoss S, Ockelford P, et al. Comparison of fixed-dose weightadjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism. JAMA 2006;296(8):935-942.

  17. Büller HR, Davidson BL, Decousus H, Gallus A, Gent M, Piovella F, et al. Fondaparinux or enoxaparin for the Initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med 2004;140(11): 867-873.

  18. Murphy KD. Mechanical thrombectomy for DVT. Tech Vasc Interv Radiol 2004;7(2):79-85.

  19. Galanaud JP, Sevestre MA, Genty C, Laroche JP, Zizka V, Bosson JL. Comparison of the clinical history of symptomatic isolated muscular calf vein thrombosis versus deep calf vein thrombosis. J Vasc Surg 2010;52(4):932-938.

  20. Rodríguez-Mańas L, Gámez-Huelgas R, Veiga-Fernández F, Ruiz GM, González JM. Thromboprophylaxis with the low-molecular-weight heparin bemiparin sodium in elderly medical patients in usual clinical practice: the ANCIANOS Study. Clin Drug Investig 2010;30(5):337-345.

  21. McLean S, Ryan K, O’Donnell JS. Primary thromboprophylaxis in the palliative care setting: a qualitative systematic review. Palliat Med 2010;24(4):386-395

  22. Dentali F, Douketis JD, Gianni M, Lim W, Crowther MA. Meta-analysis: Anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalized patients. Ann Intern Med 2007;146(4):278-288

  23. Guzmán VGG, Soto GM, Flores CA, Rico SE, Orozco LS, Nava PC, et al. Seguridad y eficacia de enoxaparina en la prevención de enfermedad tromboembólica en pacientes sometidos a cirugía de abdomen. Estudio preliminar. Cir Cir 2002;70(1):8-13.

  24. Caprini JA, Arcelus JI, Hasty JH. Tamhane AC, Fabrega F. Clinical assessment of venous thromboembolic risk in surgical patients. Semin Thromb Hemost 1991;17 (Suppl 3):304-312.

  25. Offord R, Perry D. Handbook of anticoagulation. Australian: Science Press; 2002. p. 29.

  26. Alikhan R, Cohen AT, Combe S, Samama MM, Desiardins L, Eldor A, et al. Prevention of venous thromboembolism in medical patients with exaparin: a subgroup analysis of the MEDENOX study. Blood Coagul Fibrinolysis 2003;14(4):341- 346.

  27. Lindblad B, Eriksson A, Bergqvist D. Autopsy-verified pulmonary embolism in a surgical department: analysis of the period from 1951 to 1988. Br J Surg 1991;78(7):849-852.

  28. Sandler DA, Martin JF. Autopsy proven pulmonary embolism in hospital patients: Are we detecting enough deep vein thrombosis? J R Soc Med 1989;82(4):203-205.

  29. Worsley DF, Alavi A. Comprehensive analysis of the results of the PIOPED Study. Prospective Investigation of Pulmonary Embolism Diagnosis Study. J Nucl Med 1995; 36(12):2380-2387.

  30. Anderson DR, Kahn SR, Rodger MA, Kovacs MJ, Morris T, Hirsch A, et al. Computed tomographic pulmonary angiography vs ventilation-perfusion lung scanning in patients with suspected pulmonary embolism: a randomized controlled trial. JAMA 2007;298(23):2743-2753.

  31. Ten Wolde M, Tulevski II, Mulder JW, Söhne M, Boomsma F, Mulder BJ, et al. Brain natriuretic peptide as a predictor of adverse outcome in patients with embolism. Circulation 2003;107(16):2082-2084.

  32. Usoh F, Hingorani A, Ascher E, Shiferson A, Patel N, Gopal K, et al. Prospective randomized study comparing the clinical outcomes between inferior vena cava Greenfield and TrapEase filters. J Vasc Surg 2010;52 (2):394-399.

  33. Prandoni P, Kahn SR. Post-thrombotic syndrome: prevalence, prognostication and need for progress. Br J Haematol 2009;145(3):286-295.

  34. Kahn SR, Shbaklo H, Lamping DL, Holcroft CA, Shrier I, Miron MJ, et al. Determinants of health-related quality of life during the 2 years following deep vein thrombosis. J Thromb Haemostat 2008;6(7):1105-1112.




2020     |     www.medigraphic.com